Work

An interim analysis of a phase II study using an epigenetic biomarker (CHFR methylation status) to personalize chemotherapy in patients with operable esophageal cancer.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.3_suppl.76

Authors: Ronan Joseph Kelly, John Wrangle, Russell K. Hales, Daniela Molena, Stephen C. Yang, Kristen Rodgers, Margaret Lang, Jeffrey Reynolds, Tammy Beckman, Amanda Choflet, Malcolm Brock, James Gordon Herman

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Johns Hopkins Medicine

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2589965498

Cites:

Cited by: 2

Related to: 10